Buprenorphine is a weak partial agonist that inhibits opioid receptor desensitization

Journal of Neuroscience

Volumn 29, Issue 22, 2009, Pages 7341-7348

  Virk, Michael S ^a   Arttamangkul, Seksiri ^a   Birdsong, William T ^a   Williams, John T ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE; CHLORNALTREXAMINE; ETORPHINE; G PROTEIN COUPLED RECEPTOR; METENKEPHALIN; METHADONE; MU OPIATE RECEPTOR; OXYMORPHONE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN REGION; CONTROLLED STUDY; DESENSITIZATION; DOSE RESPONSE; DRUG RECEPTOR BINDING; HYPERPOLARIZATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION;

ADRENERGIC ALPHA-AGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANALYSIS OF VARIANCE; ANIMALS; BIOPHYSICS; BRAIN; BUPRENORPHINE; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTRIC STIMULATION; ENKEPHALIN, METHIONINE; MALE; MEMBRANE POTENTIALS; MICE; MICE, TRANSGENIC; NALTREXONE; NARCOTIC ANTAGONISTS; NARCOTICS; NEURAL INHIBITION; NEURONS; PATCH-CLAMP TECHNIQUES; QUINOXALINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, OPIOID, MU; YOHIMBINE;

EID: 66749153181     PISSN: 02706474     EISSN: 15292401     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.3723-08.2009     Document Type: Article

References (46)

1. Alford DP, Compton P, Samet JH (2006) Acute pain management for patients receiving maintenance methadone or buprenorphine therapy. Ann Intern Med 144:127-134. (Pubitemid 46768231)
2. Arttamangkul S, Quillinan N, Low MJ, von Zastrow M, Pintar J, Williams JT (2008) Differential activation and trafficking of mu-opioid receptors in brain slices. Mol Pharmacol 74:972-979.
3. Bloms-Funke P, Gillen C, Schuettler AJ, Wnendt S (2000) Agonistic effects of the opioid buprenorphine on the nociceptin/OFQ receptor. Peptides 21:1141-1146.
4. Clark MJ, Linderman JJ, Traynor JR (2008) Endogenous regulators of G protein signaling differentially modulate full and partial μ-opioid agonisnts at adenylyl cyclase as predicted by a collision coupling model. Mol Pharmacol 73:1538-1548.
5. Connock M, Juarez-Garcia A, Jowett S, Frew E, Liu Z, Taylor RJ, Fry-Smith A, Day E, Lintzeris N, Roberts T, Burls A, Taylor RS (2007) Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation. Health Technol Assess 11:1-171, iii-iv. (Pubitemid 47207726)
6. Dahan A, Yassen A, Bijl H, Romberg R, Sarton E, Teppema L, Olofsen E, Danhof M (2005) Comparison of the respiratory effects of intravenous buprenorphine and fentanyl in humans and rats. Br J Anaesth 94:825-834. (Pubitemid 40754001)
7. Dahan A, Yassen A, Romberg R, Sarton E, Teppema L, Olofsen E, Danhof M (2006) Buprenorphine induces ceiling in respiratory depression but not in analgesia. Br J Anaesth 96:627-632.
8. Dang VC, Williams JT (2004) Chronic morphine treatment reduces recovery from opioid desensitization. J Neurosci 24:7699-7706. (Pubitemid 39186825)
9. Gerra G, Borella F, Zaimovic A, Moi G, Bussandri M, Bubici C, Bertacca S (2004) Buprenorphine versus methadone for opioid dependence: predictor variables for treatment outcome. Drug Alcohol Depend 75:37-45. (Pubitemid 38844575)
10. Grecksch G, Bartzsch K, Widera A, Becker A, Höllt V, Koch T (2006) Development of tolerance and sensitization to different opioid agonists in rats. Psychopharmacology 186:177-184. (Pubitemid 43727334)
11. Hayes BD, Klein-Schwartz W, Doyon S (2008) Toxicity of buprenorphine overdoses in children. Pediatrics 121:e782-e786.
12. Huang P, Kehner GB, Cowan A, Liu-Chen LY (2001) Comparison of pharmacological activities of buprenorphine and norbuprenorphine: norbuprenorphine is a potent opioid agonist. J Pharmacol Exp Ther 297:688-695. (Pubitemid 32378001)
13. Johnson RE, Chutuape MA, Strain EC, Walsh SL, Stitzer ML, Bigelow GE (2000) A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. N Engl J Med 343:1290-1297.
14. Kajiwara M, Aoki K, Ishii K, Numata H, Matsumiya T, Oka T (1986) Agonist and antagonist actions of buprenorphine on three types of opioid receptor in isolated preparations. Jpn J Pharmacol 40:95-101. (Pubitemid 16180389)
15. Kakko J, Svanborg KD, Kreek MJ, Heilig M (2003) 1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomized, placebo-controlled trial. Lancet 361:662-668. (Pubitemid 36246548)
16. Kakko J, Grönbladh L, Svanborg KD, von Wachenfeldt J, Rück C, Rawlings B, Nilsson LH, Heilig M (2007) A stepped care strategy using buprenorphine and methadone versus conventional methadone maintenance in heroin dependence: a randomized controlled trial. Am J Psychiatry 164:797-803. (Pubitemid 46808535)
17. Kakko J, Heilig M, Sarman I (2008) Buprenorphine and methadone treatment of opiate dependence during pregnancy: comparison of fetal growth and neonatal outcomes in two consecutive case series. Drug Alcohol Depend 96:69-78.
18. Koch T, Widera A, Bartzsch K, Schulz S, Brandenburg LO, Wundrack N, Beyer A, Grecksch G, Höllt V (2005) Receptor endocytosis counteraction the development of opioid tolerance. Mol Pharmacol 67:280-287. (Pubitemid 40069989)
19. Kögel B, Christoph T, Strassburger W, Friderichs E (2005) Interaction of mu-opioid receptor agonists and antagonists with the analgesic effect of buprenorphine in mice. Eur J Pain 9:599-611. (Pubitemid 41219791)
20. Law PY, Erickson LJ, El-Kouhen R, Dicker L, Solberg J, Wang W, Miller E, Burd AL, Loh HH (2000) Receptor density and recycling affect the rate of agonist-induced desensitization of mu-opioid receptor. Mol Pharmacol 58:388-398. (Pubitemid 30497483)
21. Leander JD (1987) Buprenorphine has potent kappa opioid receptor antagonist activity. Neuropharmacology 26:1445-1447. (Pubitemid 17154903)
22. Lutfy K, Eitan S, Bryant CD, Yang YC, Saliminejad N, Walwyn W, Kieffer BL, Takeshima H, Carroll FI, Maidment NT, Evans CJ (2003) Buprenorphine-induced antinociception is mediated by μ-opioid receptors and compromised by concomitant activation of opioid receptor-like receptors. J Neurosci 23:10331-10337. (Pubitemid 37444610)
23. Marquez P, Baliram R, Kieffer BL, Lutfy K (2007) The mu opioid receptor is involved in buprenorphine-induced locomotor stimulation and conditions place preference. Neuropharmacology 52:1336-1341. (Pubitemid 46601527)
24. Marquez P, Borse J, Nguyen AT, Hamid A, Lutfy K (2008) The role of the opioid receptor-like (ORL1) receptor in motor stimulatory and rewarding actions of buprenorphine and morphine. Neuroscience 155:597-602.
25. Meert TF, Vermeirsch HA (2005) A preclinical comparison between different opioids: antinociceptive versus adverse effects. Pharmacol Biochem Behav 80:309-326. (Pubitemid 40170428)
26. Osborne PB, Williams JT (1995) Characterization of acute homologous desensitization of μ-opioid receptor induced currents in locus coeruleus neurons. Br J Pharmacol 115:925-932.
27. Pergolizzi J, Böger RH, Budd K, Dahan A, Erdine S, Hans G, Kress HG, Langford R, Likar R, Raffa RB, Sacerdote P (2008) Opioids and the management of chronic severe pain in the elderly: consensus statement of an international expert panel with focus on the six clinically most often used world health organization step III opioid (buprenorphine, fentanyl, hydromorphone, methadone, morphine oxycodone). Pain Pract 8:287-313.
28. Pologruto TA, Sabatini BL, Svoboda K (2003) ScanImage: flexible software for operating laser scanning microscopes. Biomed Eng Online 2:13. (Pubitemid 38824762)
29. Raisch DW, Fye CL, Boardman KD, Sather MR (2002) Opioid dependence treatment, including buprenorphine/naloxone. Ann Pharmacother 36:312-321. (Pubitemid 34126827)
30. Richards ML, Sadée W (1985) In vivo opiate receptor binding of oripavines to mu, delta and kappa sites in rat brain as determined by an ex vivo labeling method. Eur J Pharmacol 114:343-353.
31. Sadée W, Rosenbaum JS, Herz A (1982) Buprenorphine: differential interaction with opiate receptor subtypes in vivo. J Pharmacol Exp Ther 223:157-162. (Pubitemid 12033828)
32. Selley DE, Sim LJ, Xiao R, Liu Q, Childers SR (1997) mu-Opioid receptor-stimulated guanosine-5′-O-(gamma-thio)-triphosphate binding in rat thalamus and cultured cell lines: signal transduction mechanisms underlying agonist efficacy. Mol Pharmacol 51:87-96. (Pubitemid 27049549)
33. Soyka M, Zingg C, Koller G, Kuefner H (2008) Retention rate and substance use in methadone and buprenorphine maintenance therapy and predictors of outcome: results from a randomized study. Int J Neuropsychopharmacol 11:641-653.
34. Spagnolo B, Calo G, Polgar WE, Jiang F, Olsen CM, Berzetei-Gurske I, Khroyan TV, Husbands SM, Lewis JW, Toll L, Zaveri NT (2008) Activities of mixed NOP and mu-opioid receptor ligands. Br J Pharmacol 153:609-619.
35. Teoh SK, Mendelson JH, Mello NK, Kuehnle J, Sintavanarong P, Rhoades EM (1993) Acute interactions of buprenorphine with intravenous cocaine and morphine: an investigational new drug phase I safety evaluation. J Clin Psychopharmacol 13:87-99. (Pubitemid 23087224)
36. Teoh SK, Mello NK, Mendelson JH, Kuehnle J, Gastfriend DR, Rhoades E, Sholar W (1994) Buprenorphine effects on morphine- and cocaine-induced subjective responses by drug-dependent men. J Clin Psychopharmacol 14:15-27. (Pubitemid 24076177)
37. Tzschentke TM (2002) Behavioral pharmacology of buprenorphine, with a focus on preclinical models of reward and addiction. Psychopharmacology (Berl) 161:1-16. (Pubitemid 34437963)
38. Vigezzi P, Guglielmino L, Marzorati P, Silenzio R, De Chiara M, Corrado F, Cocchi L, Cozzolino E (2006) Multimodal drug addiction treatment: a field comparison of methadone and buprenorphine among heroin- and cocaine-dependent patients. J Subst Abuse Treat 31:3-7. (Pubitemid 43949459)
39. Virk MS, Williams JT (2008) Agonist-specific regulation of μ-opioid receptor desensitization and recovery from desensitization. Mol Pharmacol 73:1301-1308.
40. Walker EA, Young AM (2001) Differential tolerance to antinociceptive effect of μ opioids during repeated treatment with etonitazene, morphine or buprenorphine in rats. Psychopharmacology 154:131-142. (Pubitemid 32186498)
41. West SL, O'Neal KK, Graham CW (2000) A meta-analysis comparing the effectiveness of buprenorphine and methadone. J Subst Abuse 12:405-414. (Pubitemid 38201228)
42. Wnendt S, Krüger T, Janocha E, Hildebrandt D, Englberger W (1999) Agonistic effect of buprenorphine in a nociceptin/OFQ receptor-triggered reporter gene assay. Mol Pharmacol 56:334-338. (Pubitemid 29347609)
43. Yamamoto T, Shono K, Tanabe S (2006) Buprenorphine activates mu and opioid receptor like-1 receptors simultaneously, but the analgesic effect is mainly mediated by mu receptor activation in the rat formalin test. J Pharmacol Exp Ther 318:206-213. (Pubitemid 43920757)
44. Yu Y, Zhang L, Yin X, Sun H, Uhl GR, Wang JB (1997) Mu opioid receptor phosphorylation, desensitization, and ligand efficacy. J Biol Chem 272:28869-28874. (Pubitemid 27498167)
45. Zaki PA, Keith DE Jr, Brine GA, Carroll FI, Evans CJ (2000) Ligand-induced changes in surface μ-opioid receptor number: relationship to G protein activation? J Pharmacol Exp Ther 292:1127-1134.
46. 35S]GTPgammaS binding to membranes: determination of potencies and efficacies of ligands. J Pharmacol Exp Ther 282:676-684.